ArticleThe American journal of pathology2015
Dendrin ablation prolongs life span by delaying kidney failure.
Article in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- The role of dendrin in IgA nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Podocyte Foot Process Effacement Precedes Albuminuria and Glomerular Hypertrophy in CD2-Associated Protein Deficient Mice.Frontiers in medicine · 2021Article
- Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.JCI insight · 2018Article
- The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.The Journal of biological chemistry · 2017Article
- A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models.Science (New York, N.Y.) · 2017Article
- Characterization of transgene expression and pDNA distribution of the suctioned kidney in mice.Drug delivery · 2017Article
- Glomerulosclerosis Induced by Deficiency of Membrane-Associated Guanylate Kinase Inverted 2 in Kidney Podocytes.Journal of the American Society of Nephrology : JASN · 2017Article
- Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.American journal of physiology. Renal physiology · 2016Article
- Validation of a Three-Dimensional Method for Counting and Sizing Podocytes in Whole Glomeruli.Journal of the American Society of Nephrology : JASN · 2016Article
- RhoA deficiency disrupts podocyte cytoskeleton and induces podocyte apoptosis by inhibiting YAP/dendrin signal.BMC nephrology · 2016Article
- Podocytes.F1000Research · 2016Review
- CD2AP, dendrin, and cathepsin L in the kidney.The American journal of pathology · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 7 institutions in 2 countries.
Funding
Abstract
Podocyte loss is central to the progression of proteinuric kidney diseases leading to end-stage kidney disease (ESKD), requiring renal replacement therapy, such as dialysis. Despite modern tools and techniques, the 5-year mortality of some patients requiring dialysis remains at about 70% to 80%. Thus, there is a great unmet need for podocyte-specific treatments aimed at preventing podocyte loss and the ensuing development of ESKD. Here, we show that ablation of the podocyte death-promoting protein dendrin delays the onset of ESKD, thereby expanding the life span of mice lacking the adapter protein CD2AP. Ablation of dendrin delays onset and severity of proteinuria and podocyte loss. In addition, dendrin ablation ameliorates mesangial volume expansion and up-regulation of mesangial fibronectin expression, which is mediated by a podocyte-secreted factor. In conclusion, onset of ESKD and death can be markedly delayed by blocking the function of dendrin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.